Could cause temporary or reversible harm; serious harm is unlikely.
Out of specification result observed in a dissolution test at the 9-month long term stability time point.
| Brand name | IMIPRAMINE PAMOATE |
| Generic name | IMIPRAMINE PAMOATE |
| Active ingredient(s) | IMIPRAMINE PAMOATE |
| Distributed by / for | Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 UNited States |
| NDC | 68180-316-06 |
| Full product label | Imipramine Pamoate Capsules 125 mg, 30-count bottle, Rx only, Manufactured for Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 UNited States. Manufactured by: Lupin Limited, Pithampur, (M.P.) 454 775 India NDC# 68180-316-06 |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | Distributed Nationwide in the USA. |
| Quantity | 1,902 bottles |
| Recall initiated | 2021-10-08 |
| Report date | 2021-10-27 |
| Recall completed | 2023-03-13 |
| Recall number | D-0027-2022 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗